tance testing (GRT) for plasma HIV RNA <500-1000 copies/ mL. This potential limitation of GRT mostly derives from the detection limits of commercial assays, as well as by the technical difficulty of many laboratories in obtaining consistent results with such LLV, yet some studies support the use of GRT, and laboratories increasingly report success in performing genotypes at this level [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
In this study, we provide data to support reliability and usefulness of GRT at viremia levels ≤500-1000 copies/mL by analyzing a large population of HIV-1-infected patients followed in central Italy who underwent GRT in routine clinical practice. Moreover, we evaluated whether different viremia levels affect the detection of drug resistance in HIV-1-infected patients who failed therapy.
MATERIALS AND METHODS

Patients
This retrospective study included 13 926 HIV-1 plasma samples that were genotyped during 1999-2012 in 2 clinical centers in Rome (Italy) for routine clinical purposes. Sample information (date of sampling, final results of sequencing, nucleotide sequences obtained, mutations found in each sequence), together with the data of patients for whom genotyping was performed (ie, viroimmunologic, clinical, and therapeutic data) were recorded in an anonymous database.
For each sample, viremia value at genotyping was known. We focused our analyses on samples with viremia >50 copies/mL (N = 12 828) that were stratified in 6 groups according to different viremia ranks (copies/mL): 50-200, 201-500, 501-1000, 1001-10 000, 10 001-100 000, and >100 000.
HIV-1 RNA Load
Depending on methodologies available during 1999-2012, plasma viremia was determined using 3 different assays: the bDNA version 3.0 (until January 2009; Bayer Corporation, Diagnostics Division, Tarrytown, New York), the Abbott RealTime HIV-1 (February 2009-February 2012; Abbott, Chicago, Illinois) and the Roche Cobas CA/CTM version 2.0 (starting from March 2012; Roche, Mannheim, Germany). These assays quantify HIV-1 RNA in the range of 50-500 000 copies/mL, 40-10 000 000 copies/mL, and 20-10 000 000 copies/mL, respectively. Previous studies demonstrated the results obtained by these assays to be well correlated, with a difference of >0.5 log 10 copies/mL, only for a few samples [27] [28] [29] .
HIV-1 pol Sequencing
HIV-1 genotype analysis was performed on plasma samples by using either the ViroSeq HIV-1 genotyping system (Abbott Molecular) and/or a homemade system, designed to improve the performance of the ViroSeq system itself [30] . Indeed, genotyping success by this commercial kit is generally guaranteed for samples with viremia ≥2000 copies/mL [31, 32] . Therefore, some steps of the ViroSeq system were modified, to also test HIV-1 pol sequences in subjects with viremia <2000 copies/mL. All of the details on the amplification and sequencing procedures can be found in the Supplementary Methods and Supplementary Figure 1 .
Subtyping Analysis
All HIV-1 pol sequences were aligned in Bio-Edit and compared to reference sequences for major HIV-1 subtypes and circular recombinant forms (CRFs), available at the Los Alamos database (http://www.hiv.lanl.gov); a phylogenetic tree was performed. To analyze trends in subtype genetic diversity over time, genetic distances were calculated by using the maximum-likelihood method in MEGA (http://www.megasoftware. net/), by using Kimura 2-parameter model as the best-fitting evolution model for tree reconstruction [33] . The tree was shown by using the graphical user interface FigTree. Subtype classification was confirmed also by the REGA subtype tool (http://www.bioafrica.net/rega-genotype/html/subtypinghiv. html), the COMET subtype tool (http://comet.retrovirology.lu/), and the DataMonkey subtype tool (http://www.datamonkey. org/dataupload_scueal.php). To improve the accuracy of recombinant and unique forms, RDP3 software (http://web.cbio. uct.ac.za/~darren/rdp.html) and Splits Tree software (http://en. bio-soft.net/tree/SplitsTree.html) were used.
Evaluation of Genotypic Success Rate and Genotyping Reliability
Genotyping success rate was determined on the overall population and according to the different viremia ranks (50-200, 201-500, 501-1000, 1001-10 000, 10 001-100 000, and >100 000 copies/ mL), regardless of the genotyping platform upgrades (equipment, kits, and reagents) that occurred from 1999 to 2012.
To ensure that there was no cross-contamination of samples analyzed and to test genotyping reliability for samples with viremia ≤500 copies/mL, a phylogenetic analysis was performed on a subgroup of 1613 pol sequences, obtained from 470 patients with at least 1 GRT performed on samples with viremia ≤500 copies/mL and at least 1 GRT with viremia >1000 copies/ mL. The phylogenetic analysis of pol sequences was performed by using the Kimura 2-parameter model of MEGA version 5.05, with the same parameters as previously described [33] .
Evaluation of Resistance in Patients Who Had Failed Therapy
The prevalence of drug resistance was evaluated, and stratified according to different viremia levels, in a subset of 3895 samples successfully genotyped from 2200 patients with complete therapeutic history, for whom a GRT was required because of virologic failure (defined as viremia >50 copies/mL). Resistance to an antiretroviral drug class was defined by the presence of at least 1 primary resistance mutation (PRM) included in the mutation list paneled by the International Antiviral Society in 2013 [34] , considering the nucleos(t)ide reverse transcriptase inhibitors (NRTIs), nonnucleos(t)ide reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). In particular, we have defined (i) the resistance to any drug class in the overall samples analyzed; (ii) the resistance to NRTIs among samples from patients who received regimens that contained NRTIs; (iii) the resistance to NNRTIs among samples from patients who received regimens that contained NNRTIs; (iv) the resistance to PIs among samples from patients who received regimens that contained ritonavir-boosted PIs (PI/r); and (v) the resistance to PIs among samples from patients who received regimens that contained ritonavir-unboosted PIs.
To better understand the clinical relevance of GRT in patients failing with LLV at the time of modern anti-HIV therapies, the prevalence of single PRMs was also evaluated on the 1317 samples from patients for whom a GRT was required because of virologic failure in the years 2008-2012. This analysis was performed by dividing the samples into 2 groups according to viremia levels ≤1000 copies/mL (n = 436) or >1000 copies/mL (n = 881).
Patient Outcome Analysis
To evaluate the effect of LLV resistance on subsequent virologic outcome, further analyses were restricted to 51 previously drugnaive patients on first-line regimens for whom a GRT was requested at viremia levels of 50-1000 copies/mL. Patients were included only if they were followed as long as they were receiving constant therapy without any changes or interruptions.
Statistical Analysis
Potential differences among the different viremia groups were evaluated as follows: (i) for the categorical variables, by the χ 2 test for trend (to compare all viremia groups) and Pearson χ 2 test or Fisher exact test when expected frequencies were <5 (to compare 2 viremia groups at a time); and (ii) for the continuous variables, by the Kruskal-Wallis test (to compare all viremia groups). Regarding the virologic outcome, Kaplan-Meier analysis was used to evaluate the probability of reaching viremia >1000 copies/mL after LLV.
In all the analyses performed, P < .05 was considered as statistically significant. The statistical programs used were R open source software (version 2.15.1) and SPSS version 19 for Windows (SPSS Inc, Chicago, Illinois). Table 1 shows the characteristics of 12 828 of 13 926 plasma samples with viremia >50 copies/mL, processed for genotyping in routine clinical practice from 1999 to 2012. Among them, 4861 (37.9%) were obtained from 4111 drug-naive patients, and 7967 (62.1%) from 3841 drug-experienced patients.
RESULTS
Study Population
Among drug-experienced patients, viremia levels of 50-1000 copies/mL accounted for 19.2% (1535/7967) of total genotypic requests ( Figure 1 ). This prevalence significantly increased over time, from 1.5% in 1999-2001 to 28.4% in 2012 (P < .001). A consistent proportion of samples with LLV was with viremia 50-500 copies/mL (1158/1535 [75.4%] vs 377 [24.6%] with viremia 501-1000 copies/mL).
Phylogenetic analysis revealed that the B subtype was the most prevalent strain (80.1%). All the other subtypes were present with a prevalence <5%; the most prevalent ones were the recombinant form CRF02_AG (4.7%) and the subtypes C (4.3%) and F (3.3%).
Genotyping Success Rate
The overall success rate of genotype amplification and sequencing was 96.4%. The rate of success was 93.2% for samples with viremia levels 501-1000 copies/mL, 88.1% for those with viremia 201-500 copies/mL, and decreased to a still-relevant 67.2% for viremia 50-200 copies/mL ( Table 2 ). The genotyping success rate was independent of subtype in all viremia groups (Table 2) . By focusing the attention on the 3 most prevalent non-B subtypes analyzed (C, F, CRF02_AG), no differences in the success rate were found (data not shown). Interestingly, the additional use of a nested polymerase chain reaction (PCR) (or modified amplification protocol; see Supplementary Methods and Supplementary Figure 1) has significantly improved the overall success rate in samples with LLV (P < .001). In particular, the nested amplification contributed to 60.4%, 55.3%, and 44.0% of the total genotypic successes with viremia levels 50-200, 201-500, and 501-1000 copies/mL, respectively. In samples with viremia levels >1000 copies/mL, the contribution of nested amplification was less relevant (from 19.2% to 3.6%; data not shown).
Genotyping Reliability
To test genotyping reliability for samples with VL ≤1000 copies/mL, we performed phylogenetic analysis on 1613 sequences from 470 patients having at least 1 genotypic sample with viremia 50-1000 copies/mL and at least another with viremia >1000 copies/mL. By evaluating each cluster, we found that sequences belonging to the same subject showed a high homology (bootstrap value >90%) in 96.4% of cases (453/470 patients) (Supplementary Figure 2) . Only 25 of 1613 sequences (1.5%) of the remaining 17 patients did not properly cluster within the same subject. Genotypic requests for 7967 plasma samples from drug experienced patients, 1999-2012. The proportions of genotypic requests stratified by different viremia ranges are represented in different shades from black to white. The differences of genotypic requests over the years in patients with viremia levels 50-1000 copies/mL vs patients with viremia levels >1000 copies/mL were evaluated by χ 2 test for trend. P < .05 was considered significant. The success of the genotypic resistance test in plasma samples from HIV-1-infected patients was evaluated on the overall population with viremia >50 copies/mL (N = 12 828) and according to subtype (B vs non-B), by stratifying for viremia ranges. The rate of genotyping success in patients with viremia <50 copies/mL was 17.5%. a Potential differences in the rate of genotypic success in B and non-B subtypes were evaluated by χ 2 test (corrected for the population size, as appropriate) or Fisher exact test, as appropriate. P < .05 was considered statistically significant.
The overall prevalence of samples with at least 1 PRM was 74% (Table 3) . PI resistance in patients treated with PI/r was in general less frequent than NRTI or NNRTI resistance (40.5%, vs 66% and 77.7%; P < .001; Table 3 ).
If we consider PI resistance only in patients for whom a firstline regimen containing a PI/r was unsuccessful, the rate of resistance dropped dramatically to 3.7%. By contrast, PI resistance in patients treated with unboosted PIs was more similar to that of those treated with an NRTI/NNRTI (61.7%) and remained high also among patients tested at first-line failure (46.6%).
The prevalence of resistance varied significantly by viremia strata (P < .001), and was characterized by a bell-shaped curve in which the highest prevalence was in the 1001-10 000 copies/mL stratum, with lower prevalence values at lower and higher viremia strata. Detection of resistance was consistent also at LLV. In particular, for viremia levels of 50-200 copies/mL, NRTI resistance was 41.3%, NNRTI resistance was 40.2%, unboosted PI resistance was 51.6%, and PI/r resistance was 20.8%. For viremia 201-500 copies/mL, rates of resistance were 62.3%, 69.3%, 30.8%, and 28.0% respectively, which increased, for viremia 501-1000 copies/mL, to 67.1%, 79.5%, 79.2%, and 39.0% for each respective drug class (Table 3) . Therefore, substantial levels of resistance can be detected also at LLV for all drug classes, with higher rates for NRTI and NNRTIs.
The distribution of drug resistance stratified for viremia was similar also considering samples only from patients failing their first-line regimen. In particular, a consistent proportion of NRTI and NNRTI resistance was found also at viremia levels 50-1000 copies/mL, whereas PI resistance was very low in samples from patients for whom a first-line PI/r-containing regimen was unsuccessful (for viremia 50-200 copies/mL: NRTI resistance, 19.2%; NNRTI resistance, 13.6%; PI/r resistance, 4.9%; for viremia 201-500 copies/mL: NRTI resistance, 38.3%; NNRTI resistance, 54.5%; PI/r resistance, 0%; for viremia 501-1000 copies/mL: NRTI resistance, 59.5%; NNRTI resistance, 73.3%; PI/r resistance, 7.1%).
The resistance to NRTI and NNRTI varied according to viremia strata also by restricting the analysis during 2008-2012, with a still-considerable prevalence of resistance in samples with viremia levels ≤1000 copies/mL (Figure 2 ). By contrast, the prevalence of PI resistance was not influenced by viremia strata because it was very limited among all failures and was almost zero in patients failing their first-line PI/r-containing regimen.
Finally, by characterizing the prevalence of each single PRM in samples genotyped during the years 2008-2012, no major differences were found by analyzing samples with viremia ≤1000 vs >1000 copies/mL (Supplementary Table 2 ). In particular, only the NNRTI PRM K103N was found with a significantly higher prevalence in patients who failed treatment with viremia >1000 copies/mL (43.3%) vs ≤1000 copies/mL (20.2%) (P < .001, after multiple comparison correction).
Virologic Outcome
By Kaplan-Meier analysis, we found that the probability of reaching viremia >1000 copies/mL after LLV was significantly higher in patients with resistance than in those without resistance, as follows: at 24 weeks, 49.7% vs 4.2%; at 48 weeks, 58.1% vs 8.7%; at 72 weeks, 72.1% vs 15.2% (P < .001; data not shown).
DISCUSSION
This study aimed at evaluating the reliability and usefulness of GRT in HIV-1-infected patients with detectable LLV, in a large data set of samples tested in 2 clinical centers in Italy. Our results showed that the genotyping success rate was 96% for the overall population. In particular, this success rate was very high also for viremia >200 copies/mL (about 88%), reaching about 93% at 501-1000 copies/mL and >97% above 1000 copies/mL. Reasonable results in terms of success rate were obtained also for samples with viremia between 50 and 200 copies/mL. The ability to easily detect samples with LLV is mainly due to the improvement of the amplification step performed in our laboratories. The success of sequencing was very similar between B and non-B strains, thus suggesting that the subtype diversity does not represent a limit. Our findings are in agreement with those recently obtained in other studies, showing a high success of amplification and sequencing also at LLV [16, 19, 21, 26] . Our results with LLV may not reflect the true population, but rather reflect founder effects, especially when nested amplification is needed. Nevertheless, phylogenetic analysis confirmed the reliability and reproducibility in our laboratories of genotypic tests at different viremia levels. Indeed, by evaluating 1613 pol sequences obtained from 470 patients with at least 2 GRTs performed at different times and with different viremia levels (ranging from <50 to >100 000 copies/mL), very high similarity among sequences from the same patient was observed.
It should be emphasized that the additional step of the nested PCR does not affect the total cost of genotyping test, because the reagents used (Supplementary Methods) are inexpensive. Indeed, by adding the nested PCR step, the total amount of HIV-1 genotyping costs is increased only by about €10-€15 per sample performed. Therefore, we can conclude that the use of GRT for treatment optimization in HIV-1-infected patients with treatment failure at LLV is in any case cost effective.
The clinical relevance of our findings is related to the fact that in the last few years there has been an increased demand for GRTs for drug-experienced patients failing with LLV (mainly ≤500 copies/mL, as shown in our analysis; Figure 1 ), explained by a greater tendency to closely monitor patients in terms of response to treatment and drug resistance. In our data set the proportion of requests from patients failing therapy with LLV has been about 30% since 2009. Resistance to an antiretroviral drug class was defined by the presence of at least 1 PRM included in the mutation list paneled by the International AIDS Society in 2013 [34] , considering the NRTIs, NNRTIs, and PIs. In particular, we have defined (i) the resistance to any drug class in the overall samples analyzed; (ii) the resistance to NRTIs among samples from patients who received regimens that contained NRTIs; (iii) the resistance to NNRTIs among samples from patients who received regimens that contained NNRTIs; (iv) the resistance to PIs among samples from patients who received regimens that contained ritonavir-boosted PIs; and (v) the resistance to PIs among samples from patients who received regimens that contained ritonavir-unboosted PIs. In all the analyses performed, P < .05 was considered statistically significant. Abbreviations: %, proportion of samples with at least 1 PRM according to drug class; IQR , interquartile range; NNRTI, nonnucleos(t)ide reverse transcriptase inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitor; PI, protease inhibitor; PRM, primary resistance mutation. a Potential differences in the percentage of resistance among the different viremia ranges were evaluated by the χ 2 test for trend. b Potential differences in the number of PRMs among the different viremia ranges were evaluated by the Kruskal-Wallis test.
Moreover, our results corroborate the already discussed recruitment about drug resistance presence also at viremia levels ≤1000 copies/mL [26, [35] [36] [37] , underlining the importance of GRTs also at LLV for the optimization of therapy in patients under virologic failure. In this regard, it should be emphasized that the optimization of the sequencing protocol in the last years has led to a higher accuracy in detecting the PRMs for each viremia level. In our study, a considerable prevalence of resistance was found also at LLV among the samples analyzed from patients for whom therapy was unsuccessful. This finding proves that the detection of drug resistance is not a rare event in these low viremia ranges.
A decline in the prevalence of PRMs was observed also at the very high viremia strata among drug-experienced individuals. This decline is likely to reflect suboptimal medication adherence, with lower drug resistance selection [35] .
A considerable prevalence of resistance to NRTIs and NNRTIs at LLV was found also when the analysis was restricted to 1317 samples from patients failing therapy in the last few years. This prevalence can be due to the large usage of lowgenetic-barrier drugs such as lamivudine/emtricitabine or efavirenz/nevirapine. By the evaluation of the effect of LLV resistance on subsequent virologic outcome, we found that the probability of reaching viremia >1000 copies/mL by 72 weeks after LLV was significantly higher in patients with resistance than in those without resistance. This strongly suggests that the early detection of resistance (when viremia is still <1000 copies/mL) may prevent the evolution toward (i) a virologic failure with higher viremia and (ii) the accumulation of additional mutations, thus affecting the choice of future therapeutic regimens. A potential limitation of this analysis could be it that was performed only on a very small data set of patients. In line with our data, a recent study, performed in a larger cohort of patients, confirmed that LLV resistance is predictive of subsequent virologic failure [37] . Taken together, these results reinforce the concept that GRT may be useful in the management of failure even at LLV.
Data presented in our study, in agreement with previous articles [35, 36] and with data recently presented [26, 37, 38] , suggest that newer guidelines may reconsider the importance of GRT in clinical practice even at LLV. Indeed, despite the technical improvements achieved in the last few years, treatment guidelines still do not usually recommend GRT in patients with a plasma viral load ranging between 50 and 1000 copies/mL [2, 4] .
In conclusion, our study, carried out in standard clinical practice, confirms that drug resistance mutations can be detected even at low viral load, regardless of the antiretroviral target genes, and can remarkably reduce the current therapeutic options for further regimens. Our findings emphasize the importance of using the genotypic test at the first treatment failures even at low viremia, to guide the choice of an effective alternative regimen.
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Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author. Figure 2 . Resistance to nucleos(t)ide reverse transcriptase inhibitor (NRTI), nonnucleos(t)ide reverse transcriptase inhibitor (NNRTI), or ritonavir-boosted protease inhibitor (PI/r) classes in samples collected from January 2008 to December 2012 stratified for plasma viremia ranges. Analysis was performed on 1317 samples from patients for whom NRTI, NNRTI, or ritonavir-boosted PI treatment failed. Resistance was defined as the presence of at least 1 primary NRTI, NNRTI, or PI resistance mutation among those paneled by the International AIDS Society-USA [34] . Potential differences in the percentage of resistance among the different viremia ranges were evaluated by χ 2 test for trend. P < .05 was considered significant.
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